MYLAN THWARTED IN HOSTILE TAKEOVER OF PERRIGO
________________________________________________________
Case Study Objectives: To illustrate how
• Institutional investors can impact corporate decisions
• Current strategies can limit future options
• Good governance trumps bad management and
• Hubris can derail good decision making
__________________________________________________________________________________
Things looked good for Mylan NV, a leading generic pharmaceutical drug maker, midday on November 13, 2015 as the early
results of the firm’s campaign to acquire Perrigo appeared promising. The votes of more and more index-fund shares
supported Mylan’s proposed takeover of Perrigo Co., a maker of store-branded generic drugs. This date marked the last day
Perrigo shareholders could tender their shares, a process that had begun with Mylan’s initiation of a tender offer for a simple
But the heady feeling among Mylan’s board of directors and senior management was soon to turn grim. By evening,
Mylan’s position appeared to weaken when a tally of votes by the national stock clearinghouse, Deposit Trust Corporation,
showed that Mylan was short by about 18 million shares of the number of needed to gain a controlling interest in Perrigo.
Had they won control of the firm, Mylan reasoned they could implement a backend merger at a later date to “squeeze out” the
shareholders who had been unwilling to tender their shares.
Nearly all the major mutual funds supported Perrigo, with only Vanguard Group supporting Mylan. Other major mutual
fund groups did not even vote, including Blackrock, State Street Global Advisers, and Fidelity Investments. Despite an
aggressive marketing campaign to garner investor support, Mylan failed to convince enough investors that they would be
better off owning shares in a combined Mylan/Perrigo company. In the end, Mylan was able to garner only 40% of Perrigo’s
outstanding common shares.
Even though Mylan had promised to make certain changes to its questionable governance practices immediately following
its acquisition of Perrigo, the declining value of its shares made the Mylan shares less attractive. Teva Pharmaceuticals bid to
acquire Mylan earlier in 2015 had inflated the value of Mylan’s shares to reflect most of the anticipated premium. Mylan was
using the inflated value of its shares to make a bid for Perrigo. When Teva later withdrew its offer, Mylan shares plummeted,
reducing the premium to Perrigo’s share price from 34% when the offer was first made to less than 3%. Ultimately, concerns